Filtered By:
Source: International Journal of Cardiology
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 880 results found since Jan 2013.
A new era in the management of type 2 diabetes: is cardioprotection at long last a reality!
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. These two medications act through different mechanisms and has consequently shown different patterns of cardiovascular benefit.
Source: International Journal of Cardiology - November 11, 2016 Category: Cardiology Authors: Xavier Rossello, Derek M. Yellon Tags: Editorial Source Type: research
A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. These two medications act through different mechanisms and has consequently shown different patterns of cardiovascular benefit.
Source: International Journal of Cardiology - November 11, 2016 Category: Cardiology Authors: Xavier Rossello, Derek M. Yellon Tags: Editorial Source Type: research
Simplifying electrocardiographic assessment in STEMI reperfusion management: Pros and Cons
Current guidelines on STEMI reperfusion management do not incorporate further electrocardiographic details over the presence of significant ST elevation. Fibrinolysis is considered an alternative therapy to primary PCI if there is a long PCI-related delay, but the 2 therapies should not be combined. Meanwhile, reperfusion for ischemic stroke has evolved on mechanistic understanding - reperfusion benefit being greatest in the patient with small “core” infarct and large ischemic “penumbra”. Fibrinolysis is not regarded as an alternative to mechanical thrombectomy, and the 2 therapies can be combined.
Source: International Journal of Cardiology - November 9, 2016 Category: Cardiology Authors: Cheuk-Kit Wong Tags: Review Source Type: research
Usefulness of CHADS2 Score for Prognostic Stratification of Patients with Coronary Artery Disease: A Systematic Review and Meta-analysis of Cohort Studies
To evaluate the role of CHADS2 score on predicting ischaemic stroke or transient ischaemic attack (TIA) and death in patients with coronary artery disease (CAD), irrespective of the presence or absence of atrial fibrillation (AF)
Source: International Journal of Cardiology - November 7, 2016 Category: Cardiology Authors: Xiaobo Zhou, Kaiwu Cao, Shuangqing Kou, Shencheng QU, Hongling Li, Ying Yu, Cong Wang, Yu Liu, Pengying Li, Dan Li Source Type: research
Extracranial carotid artery stenosis and outcomes of patients undergoing transcatheter aortic valve replacement
Transcatheter aortic valve replacement (TAVR) is an alternative to open cardiac surgery in selected patients with severe aortic stenosis (AS). Carotid artery stenosis (CAS) has been associated with an increased risk of stroke following cardiac surgery, although the association between CAS and outcomes following TAVR is unclear. We therefore sought to study the prognostic impact of CAS on outcomes of patients undergoing TAVR.
Source: International Journal of Cardiology - November 7, 2016 Category: Cardiology Authors: Jeremy Ben-Shoshan, David Zahler, Arie Steinvil, Shmuel Banai, Gad Keren, Natan M. Bornstein, Ariel Finkelstein, Amir Halkin Source Type: research
Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation
Several studies have compared the discriminative performances of CHA2DS2-VASc and ATRIA scores, but the results are still disputed. Therefore, we aimed to explore their predictive abilities regarding stroke and thromboembolism (TE) risk in AF patients.
Source: International Journal of Cardiology - November 7, 2016 Category: Cardiology Authors: Wengen Zhu, Linghua Fu, Ying Ding, Lin Huang, Zhenyan Xu, Jinzhu Hu, Kui Hong Source Type: research
Levels of nitric oxide pathway parameters may depend on heteroplasmy rates of the m.3243A > G mutation
Concerning the article by Hanff et al. about L-arginine/nitric-oxide(NO)-pathway and arginine:glycine-amidinotransferase(AGAT) activities in a 57yo male with mitochondrial encephalopathy, lactacidosis, and stroke-like-episode(MELAS)-syndrome due to the m.3243A>G mutation [1]. we raise the following concerns.
Source: International Journal of Cardiology - November 3, 2016 Category: Cardiology Authors: Josef Finsterer, Sinda Zarrouk-Mahjoub Source Type: research
Usefulness of stroke volume monitoring during upright ramp incremental cycle exercise in young patients with Fontan circulation
Aerobic capacity (VO2 max) of patients with Fontan circulation (FC) is lowest within patients with congenital heart disease. The reasons have not been completely elucidated.
Source: International Journal of Cardiology - October 28, 2016 Category: Cardiology Authors: Antoine Legendre, Aurore Guillot, Magalie Ladouceur, Damien Bonnet Source Type: research
Influence of Statin Therapy at Time of Stroke Onset on Functional Outcome among Patients with Atrial Fibrillation
Statin pretreatment has been associated with reduced infarct volume in nonlacunar strokes. The effect of statins on functional outcomes of strokes related to atrial fibrillation (AF) is unknown. We aimed to define the influence of prestroke statin use on functional outcome in AF.
Source: International Journal of Cardiology - October 23, 2016 Category: Cardiology Authors: Darae Ko, Jonathan L. Thigpen, James A. Otis, Kristen Forster, Lori Henault, Emily Quinn, Yorghos Tripodis, Peter B. Berger, Nita Limdi, Elaine M. Hylek Source Type: research
Persistent atrial standstill with coronary and cerebral embolism treated with left atrial appendage closure
Systemic arterial embolism or stroke occurs predominantly in elderly patients with persistent atrial fibrillation. Here we report a young patient with persistent atrial standstill and left atrial appendage thrombus, leading to coronary and cerebral embolic events.
Source: International Journal of Cardiology - September 30, 2016 Category: Cardiology Authors: Zhonghua Sun, Yanmin Zhou, Ding Zhou, Yat-Yin Lam, Yunzhou Huang, Jian Zhang, Yuanlu Chen, Xiangqian Qi Tags: Correspondence Source Type: research
Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban
The high risk of both stroke and major bleeding in atrial fibrillation (AF) patients with chronic kidney disease (CKD) defines an important population for whom the assessment of the balance between the risk of ischemic stroke and of bleeding is essential. The use of novel oral anticoagulants (NOACs) may be a viable option in this population due to their greater net clinical benefit than warfarin, as demonstrated by the results of the clinical phase III trials. NOACs have been found to have a greater net clinical benefit than warfarin in patients at high risk of either stroke (CHADS2 ≥1 or CHA2DS2-VASc score≥2) or bleeding (HAS-BLED≥3).
Source: International Journal of Cardiology - September 30, 2016 Category: Cardiology Authors: Francesco Pelliccia, Salvatore Rosanio, Giuseppe Marazzi, Sara Poggi, Alessandra Tanzilli, Cesare Greco, Carlo Gaudio, Giuseppe Rosano Tags: Review Source Type: research
New oral anticoagulants versus Warfarin in patients undergoing cardioversion of atrial fibrillation
Atrial fibrillation (AF) is the most frequently observed sustained cardiac arrhythmia, with a prevalence of about 1% in the general population [1]. Either pharmacological or electrical cardioversion can be used in symptomatic patients to restore sinus rhythm [1,2]. However, cardioversion carries a not negligible peri-procedural risk of thromboembolic events, with stroke rates between 5 and 7% in non-anticoagulated patients [3]. Such incidence of thromboembolic events is reduced by Warfarin therapy to lower than 1% [4].
Source: International Journal of Cardiology - September 30, 2016 Category: Cardiology Authors: Giuseppe And ò, Olimpia Trio Tags: Correspondence Source Type: research
Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant
Atrial fibrillation (AF) and heart failure (HF) frequently coexist. AF is identified in approximately one third of patients with HF and is linked to increased morbidity and mortality than from either condition alone. AF is relatively more common in HF with preserved ejection fraction (HFpEF) than with reduced ejection fraction (HFrEF). Nevertheless, the risk of stroke and systemic embolism (SSE) is significantly increased with both HF types and the absolute risk is heavily influenced by the presence and severity of associated additional stroke risk factors.
Source: International Journal of Cardiology - September 29, 2016 Category: Cardiology Authors: Louise A E Brown, Christopher J Boos Tags: Review Source Type: research
30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death
Long-term nationwide trends in atrial fibrillation (AF) incidence and 5-year outcomes are rare.
Source: International Journal of Cardiology - September 20, 2016 Category: Cardiology Authors: Morten Schmidt, Sinna Pilgaard Ulrichsen, Lars Pedersen, Hans Erik B øtker, Jens Cosedis Nielsen, Henrik Toft Sørensen Source Type: research
The C of CHADS: Historical Perspective and Clinical Applications for Anticoagulation in patients with Non Valvular Atrial Fibrillation and Congestive Heart Failure
The risk stratification of patients with coexisting non valvular atrial fibrillation and congestive heart failure, is often a clinical challenge, as the definitions of congestive heart failure in the popular CHADS2 and CHA2DS2VASc scoring systems, and amongst major clinical trials on Warfarin and Novel Oral Anticoagulants (NOAC) have heterogeneity. Available evidence reveals that any heart failure and/or left ventricular systolic dysfunction is associated with higher rates of stroke/systemic embolism and bleeding in patients with non valvular atrial fibrillation compared to patients without heart failure and normal left ventricular function.
Source: International Journal of Cardiology - September 16, 2016 Category: Cardiology Authors: Y Chugh, RT Faillace Tags: Editorial Source Type: research
